
Oncology NEWS International
- Oncology NEWS International Vol 5 No 1
- Volume 5
- Issue 1
Zoladex Gets Indication for Advanced Breast Ca
WILMINGTON, Del--Zoladex (goserelin acetate implant), Zeneca Pharmaceuticals' gonadotropin-releasing-hormone (GnRH) agonist, has received approval for use in the treatment of advanced breast cancer in premenopausal and perimenopausal women.
WILMINGTON, Del--Zoladex (goserelin acetate implant), Zeneca Pharmaceuticals'gonadotropin-releasing-hormone (GnRH) agonist, has received approvalfor use in the treatment of advanced breast cancer in premenopausaland perimenopausal women.
The agent was introduced in the United States for the treatmentof advanced prostate cancer in 1989 and for the treatment of endometriosisin 1993.
Zoladex, given by injection once a month, acts on the pituitarygland to cause decreased production of estrogen by the ovaries.This lowers serum estrogen levels to concentrations typical ofpostmenopausal women, reducing estrogen stimulation of breasttumor growth.
The new indication is based on results of clinical trials involvingmore than 800 women in North America and Europe, showing responserates and survival benefits comparable to those achieved by oophorectomy,the company said.
Articles in this issue
over 30 years ago
HCFA Reevaluations May Affect Chemo Administration Cost Codesover 30 years ago
Breast Cancer Info Now on Internetover 30 years ago
HDC/ABMT Has Benefits in Multiple Myelomaover 30 years ago
Reporting of Study Comparing Casodex, Eulexin Is Questionedover 30 years ago
Limits on Tamoxifen Duration Questionedover 30 years ago
ACRO Forecasts Radiologist Surplusover 30 years ago
Potency Status Before RT, Not Dose, Determines Post-RT Functionover 30 years ago
Dr. Klausner Outlines Goals for NCIover 30 years ago
Difficulties in Translating Relative Risks Into Absolute RiskRelated Content




107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer (ABC)



















































